Dr Nitzan Rosenfeld receives​ EACR Cancer Researcher Award

Senior Group Leader Dr Nitzan Rosenfeld has been announced as the winner of the 2020 Pezcoller Foundation – EACR Cancer Researcher Award.

The Pezcoller Foundation – EACR Cancer Researcher Award celebrates academic excellence and achievements in the field of cancer research. The award is presented at the annual EACR Congress to a researcher of excellence with no more than 15 years post-doctoral experience (or equivalent degree), with at least five years spent in Europe.

Dr. Rosenfeld will give the Pezcoller Foundation – EACR Cancer Researcher Award Lecture at the EACR 2020 Congress (17-20 June 2020, Torino, Italy), and also receive a €10,000 honorarium.

Dr. Nitzan Rosenfeld is a recognised expert in liquid biopsy and translational cancer research. He initially studied Physics, followed by training in Systems Biology, obtaining a PhD from the Weizmann Institute of Science. Moving into biotech, Dr. Rosenfeld led a Computational Biology team developing molecular diagnostic tests for oncology.

Since 2009 he has lead a research group at the Cancer Research UK Cambridge Institute, University of Cambridge, inventing and pioneering liquid biopsy approaches. The group established applications of circulating tumour DNA (ctDNA) sequencing through widely-cited publications describing whole exome, hybrid capture, and amplicon-based methods to analyze ctDNA from blood samples of cancer patients. Dr. Rosenfeld’s work is funded by CRUK, ERC and others, and has been recognised by distinguished awards from CRUK and BACR, the Foulkes Foundation Medal, and the Meyenburg Cancer Research Award. He has trained and mentored scientists that now lead translational research projects across academia and industry.

In 2014, Dr. Rosenfeld and colleagues founded Inivata, a cancer genomics company unlocking the potential of liquid biopsies to transform the care of cancer patients. Its innovative InVision™ platform, based on pioneering research from the CRUK Cambridge Institute, is employed by leading institutes for cancer research and clinical diagnostics.